Merck and Japan Tobacco collaborate on Calcium Sensing Receptor antagonist « GPCR News

Tags

5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
September 2008

M T W T F S S

« Aug Oct »

1 2 3 4 5 6 7

8 9 10 11 12 13 14

15 16 17 18 19 20 21

22 23 24 25 26 27 28

29 30

Merck and Japan Tobacco collaborate on Calcium Sensing Receptor antagonist

Posted on September 25, 2008 by crimsoncanary

Merck have partnered with Japan Tobacco to commercialize JTT-305, a Ca sensing receptor antagonist with potential in the treatment of osteoporosis

Filed under: Uncategorized | Tagged: antagonist, Ca sensing receptor, Calcium sensing receptor, Japan Tobacco, JTI, Licensing, Merck

« J&J publish series of histamine H3 antagonists Recordati publish series of 5-HT1A Full Agonists »

Leave a Reply